Cargando…

Movement disorders emergencies.

Detalles Bibliográficos
Clasificación:	Libro Electrónico
Formato:	eBook
Idioma:	Inglés
Publicado:	[S.l.] : Academic Press, 2023.
Colección:	International review of movement disorders ; 6
Temas:	Movement disorders. Emergency medicine. Emergency Medicine M�edecine d'urgence.
Acceso en línea:	Texto completo

Tabla de Contenidos:

Intro
Movement Disorders Emergencies
Copyright
Contents
Contributors
Preface
Chapter One: Management of acute non-motor symptoms of Parkinson�s disease
1. Introduction
2. Park-depression/anxiety
2.1. Introduction to the park-depression/anxiety subtype
2.1.1. Acute emergencies within the park-depression/anxiety subtype
2.1.1.1. Acute depression
2.1.1.2. Dopamine agonist withdrawal syndrome
3. Park-sleep
3.1. Introduction to the park-sleep subtype
3.1.1. Acute emergencies within the park-sleep subtype
3.1.1.1. Sudden onset of sleep
4. Park-autonomic
4.1. Introduction to the park-autonomic subtype
4.1.1. Emergencies within the park-autonomic subtype
4.1.1.1. Acute constipation
5. Acute psychosis and acute delirium
5.1. Acute psychosis
5.2. Acute delirium
6. Parkinsonism hyperpyrexia syndrome and neuroleptic malignant syndrome
7. Conclusion
References
Further reading
Chapter Two: Movement disorders emergencies in metabolic disorders
1. Hypokinetic disorders
1.1. Tetany
1.2. Catatonia
1.3. Parkinsonism
1.3.1. Alcohol withdrawal
1.3.2. Central pontine or extrapontine myelinolysis
1.3.3. Calcium and parathyroid homeostasis
1.3.4. Associated to uraemia and renal failure
1.3.5. Diabetes mellitus
2. Hyperkinetic disorders
2.1. Tremor
2.1.1. Kidney disorders
2.1.1.1. Direct consequences of renal failure
2.1.1.2. Consequences of electrolyte imbalance in renal failure
2.1.1.3. Consequences of dialysis in renal failure (manganese accumulation in the globus pallidus has been reported in pa ...
2.1.2. Liver failure
2.1.2.1. Acquired hepatocerebral degeneration (AHD)
2.1.2.2. Combined hepatic and neurological syndromes secondary to intake alcohol
2.1.3. Thyroid disorders and tremor
2.1.3.1. Hyperthyroidism.
2.1.4. Wilson disease
2.2. Myoclonus
2.2.1. Acute liver failure (ALF)
2.2.2. Uremia
2.2.3. Electrolyte disturbances
2.2.4. Manganese poisoning (MP)
2.2.5. Drugs-induced myoclonus
2.2.6. Glucose alterations
2.3. Dystonia
2.3.1. Status dystonicus (DS)
2.3.2. Acute dystonic reactions in metabolic disorders
2.3.2.1. Biotin-thiamine-responsive basal ganglia disease (BTBGD)
2.3.2.2. Osmotic demyelinating syndrome (ODS)
2.3.2.3. Mitochondrial encephalopathy and other metabolic disorders
2.4. Chorea
2.4.1. Glycemia
2.4.2. Others
3. ATAXIA
3.1. Ataxia associated to vitamin deficiencies
3.2. Hypomagnesemia
References
Chapter Three: Acute psychiatric problems in movement disorders
1. Introduction
2. Parkinson�s disease (PD)
2.1. Psychiatric symptoms in PD
2.1.1. Psychosis
2.1.2. Impulse-control disorders and dopamine-dysregulation syndrome
2.1.3. Management and treatment of acute psychosis problems in PD
3. Dementia with Lewy bodies (DLB)
3.1. Psychiatric symptoms in DLB
3.2. Approaches to managing acute psychiatric problems in DLB
4. Atypical Parkinsonism
5. Huntington�s disease (HD) and choreas
5.1. Psychiatric symptoms in HD and choreas
5.1.1. Behavioral changes
5.1.2. Mood disorders
5.1.3. Psychosis
5.2. Approaches to treating acute psychiatric problems in HD and choreas
6. Neuroacanthocytosis
6.1. Psychiatric symptoms in neuroacanthocytosis
6.2. Strategies for managing acute psychiatric problems in neuroacanthocytosis
7. Tic disorders
7.1. Psychiatric symptoms associated with Tic disorders
7.2. Addressing acute psychiatric problems in Tic disorders
8. Dystonia
8.1. Psychiatric symptoms in dystonia
8.2. Management of acute psychiatric problems in dystonia
9. Myoclonus
9.1. Psychiatric symptoms in myoclonus.
10. Discussion and conclusion
References
Chapter Four: Emergencies in deep brain stimulation
1. Introduction
2. Complications and emergencies in DBS
2.1. Surgery-related emergencies
2.1.1. Asymptomatic/symptomatic cerebrovascular accidents
2.1.1.1. Management
2.1.2. Oedema
2.1.2.1. Management
2.1.3. Seizures
2.1.3.1. Management
2.1.4. Air embolus
2.1.4.1. Management
2.1.5. Dyskinetic storm
2.1.5.1. Management
2.2. Hardware-related emergencies
2.2.1. Infections
2.2.1.1. Management
2.2.2. Skin erosions-without infections
2.2.3. Hardware failure
2.2.3.1. ``Twiddler�s syndrome��
2.2.3.2. ``DBS withdrawal syndrome��
2.2.3.3. Management
2.3. Medication titration-related emergencies
2.3.1. Dopamine withdrawal syndrome
2.3.1.1. Management
2.4. Stimulation-related emergencies
3. Conclusions
References
Chapter Five: Emergencies in pump therapies
1. Introduction
2. Intestinal levodopa infusion
2.1. LCIG therapy
3. Limitations of intestinal levodopa infusion therapy
3.1. Surgery
3.2. Pump and tube
3.3. Prevalence of complications
3.4. LECIG therapy
4. Limitations of subcutaneous infusion therapy
4.1. Apomorphine infusion
4.2. Possible side effects and treatment options
4.2.1. Neuropsychiatric side effects
4.3. Nausea/treatment of nausea
4.3.1. Postural hypotension/treatment of postural hypotension
4.3.2. Hemolytic anemia/treatment of hemolytic anemia
4.3.3. Sedation, somnolence, sleep attacks
4.4. Impulse control disorders (ICD)
4.5. Hypersexuality
4.6. Overdose
4.6.1. Foslevodopa/foscarbidopa
5. Conclusion
References
Chapter Six: Acute Parkinsonism: From viruses to non-viruses etiologies
1. Introduction
2. Acute parkinsonism with immune pathogenesis
2.1. Infectious parkinsonism.
2.1.1. Classification
2.2. Epstein-Barr virus
2.3. Human immunodeficiency virus
2.4. Coxsackie virus
2.5. Flaviviruses
2.6. COVID-19
2.7. Other infectious causes
2.8. Autoimmune and paraneoplastic
2.8.1. Anti-IgLON5 disease
2.8.2. Anti-Ma-2 antibodies
2.9. GAD-65 antibodies
2.10. Systemic autoimmune diseases
2.11. Immune checkpoint inhibitors (ICIs) and parkinsonism
2.12. Clinical features, pathogenesis, diagnosis and management
2.13. Noninfectious acute parkinsonism
2.13.1. Structural lesions
2.14. Drugs-induced Parkinsonism
2.15. Antipsychotics
2.16. Non-antipsychotic neuroleptics
2.17. Non-neuroleptics
2.18. Toxin-induced parkinsonism
2.19. Carbon monoxide
2.20. Manganese
2.21. MPTP
2.22. Rotenone
2.23. Psychiatric causes of acute parkinsonism
3. Conclusions
References
Chapter Seven: Acute dystonia and status dystonicus dystonia
1. Introduction
2. Acute dystonia
2.1. Definition
2.2. Epidemiology
2.3. Medication-induced dystonia
2.3.1. Antipsychotics
2.3.2. Antiemetics
2.3.3. Antiepileptics
2.3.4. Additionaldrugs
2.4. Pathophysiological mechanism
2.4.1. Dopaminergic receptor blockade
2.5. Clinical presentation
2.6. Differential diagnosis-ADR mimics
2.7. Management
3. Status dystonicus
3.1. Definition
3.2. Epidemiology
3.3. Etiology
3.4. Pathophysiological mechanism
3.5. Clinical features
3.6. Complications
3.7. Differential diagnosis
3.8. Management
4. Conclusion and summary
References
Chapter Eight: Emergencies in tic and choreic disorders
1. Emergencies in choreic disorders
2. Emergencies related to acute chorea/ ballism
2.1. Chorea related to endocrinal disorders
2.2. Post stroke hemichorea/ hemiballismus
2.3. Autoimmune/inflammatory chorea
2.4. Pregnancy and chorea.
2.5. Acute chorea due to infections
2.6. Acute chorea related to inherited metabolic and genetic disorders
2.7. Drug induced chorea/ballism
2.7.1. Patient vignettes
2.7.2. Levodopa induced dyskinesia
2.7.3. Tardive dyskinesia
2.7.4. Central nervous system stimulants and chorea
2.7.5. Non-neuroleptic drug-induced chorea
2.8. DBS and ablative surgery induced chorea
2.9. Emergencies related to associated manifestations
2.10. Emergencies related to anti-chorea therapies
3. Emergencies in tic disorders
3.1. Severe exacerbation of tics and tic-related injuries
3.2. Self-injurious behavior
3.3. Emergencies secondary to exacerbations of comorbid neuropsychiatric disorders
3.4. Emergencies secondary to side effects of therapy
3.5. Emergencies observed in patients with secondary tic disorders
4. Conclusions
References
Chapter Nine: Telemedicine and digital health solutions for managing movement disorders emergencies
1. Introduction
1.1. Movement disorders emergencies
1.2. Impact of COVID-19 pandemic on movement disorders patients� care
2. Telemedicine-Current knowledge
2.1. Benefits and limitations of telemedicine
2.2. Telemedicine in remote and underserved regions
2.3. Telemedicine technologies and models
3. Telemedicine in the diagnosis of movement disorders and movement disorders emergencies
4. Telemedicine in the monitoring and treatment of movement disorders and movement disorders emergencies
5. Movement disorders patient education and satisfaction with telemedicine
6. Conclusions
References
Further reading
Chapter Ten: Laryngeal dystonia and abductor paresis in multiple system atrophy and other conditions
1. Introduction
2. Laryngeal dystonia (LD)
2.1. Terminology, types, risk factors
2.2. Patho-neurophysiology of LD.

Movement disorders emergencies.

Ejemplares similares